# 177Lu-CTR-FAPI for the Treatment of Thyroid Cancer

> **NCT07438847** · PHASE1 · RECRUITING · sponsor: **SHAOYAN LIU** · enrollment: 12 (estimated)

## Conditions studied

- Thyroid Cancer

## Interventions

- **DRUG:** 177Lu-CTR-FAPI therapy

## Key facts

- **NCT ID:** NCT07438847
- **Lead sponsor:** SHAOYAN LIU
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-01
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2026-02-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07438847

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07438847, "177Lu-CTR-FAPI for the Treatment of Thyroid Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07438847. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*